AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4

Glycigon-M Tablet

Prescription Icon
Prescription Required

Marketer

Aristo Pharmaceuticals Pvt Ltd

Salt Composition

Gliclazide (80mg) + Metformin (500mg)

Overview Glycigon-M Tablet

Diabetace-Duo tablets are a dual-action antidiabetic medication, formulated for adult patients with type 2 diabetes. This combined formulation helps manage blood glucose levels. Always take Diabetace-Duo with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on your blood sugar readings. Continued use is crucial, even with well-controlled blood sugar, as abrupt cessation can lead to dangerously elevated glucose levels, increasing the risk of kidney complications, vision impairment, neuropathy, and limb loss. Diabetace-Duo is part of a comprehensive diabetes management plan, incorporating a balanced diet, regular exercise, and weight management as directed by your doctor. Lifestyle modifications are integral to successful diabetes control. Common side effects include hypoglycemia (low blood sugar), characterized by sweating, dizziness, headache, and tremors; constipation; and nausea. Always carry a rapid-acting glucose source (e.g., sugary snacks, juice) to counteract hypoglycemia, and maintain regular mealtimes. Alcohol consumption should be minimized due to its potential to exacerbate hypoglycemic episodes. Other possible side effects include altered taste, diarrhea, abdominal discomfort, and upper respiratory infections. Weight gain may occur in some individuals. Diabetace-Duo is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Prior heart disease should be disclosed to your physician before commencing treatment. Pregnant or lactating women should seek medical counsel before using Diabetace-Duo. Regular blood glucose monitoring is essential, and your doctor may order blood tests to track blood cell counts and liver function.

Primary Ingredients of Glycigon-M Tablet

No text provided to rephrase.

Uses of Glycigon-M Tablet

Adult-onset diabetes

Major Benefits of Glycigon-M Tablet:

Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Glycigon-M Tablets should be administered with food.

Common Side effects of Glycigon-M Tablet:

  • Hypoglycemia (low blood glucose level)
  • Headache
  • Dizziness
  • Diarrhea
  • Upper respiratory tract infection
  • Nausea
  • Flatulence
  • Constipation

How to use Glycigon-M Tablet:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the tablet whole; do not chew, crush, or divide it. Glycigon-M Tablets should be administered with food.

How Glycigon-M Tablet works:

Glycigon-M tablets contain gliclazide and metformin, two medications used to manage blood sugar levels.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Alcohol consumption alongside Glycigon-M Tablets is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

Use of Glycigon-M Tablets is contraindicated during pregnancy due to established risk to the fetus. In exceptional life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Physician consultation is mandatory.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Use of Glycigon-M Tablets while breastfeeding is likely inadvisable. Available human data indicate a potential for the medication to transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving may be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Glycigon-M Tablets cautiously, potentially requiring dosage modification. Consult your physician for guidance. Glycigon-M Tablets are contraindicated in individuals with severe kidney disease. Routine monitoring of renal function is recommended during treatment.

LiverLiverCAUTION

Patients with liver impairment should use Glycigon-M Tablets cautiously, potentially requiring dose modification. Consult a physician before use. A reduced initial dose is typically recommended for those with mild to moderate liver disease; Glycigon-M Tablets are contraindicated in patients with severe hepatic dysfunction.

What if you forget to take Glycigon-M Tablet :

Should you forget a Glycigon-M Tablet dose, administer it promptly. Nevertheless, if your next dose is imminent, omit the missed one and resume your usual dosing pattern. Avoid taking a double dose.

Facts to Know About Glycigon-M Tablet

LabelValue
Potential for Dependence None.
Medication Classification Medication for diabetes

FAQs on Glycigon-M Tablet

Glycigon-M tablets contain gliclazide and metformin, working synergistically to manage type 2 diabetes mellitus in adults. This dual-action medication enhances blood glucose control when combined with a healthy diet and physical activity. Gliclazide stimulates insulin secretion from the pancreas, while metformin reduces hepatic glucose production and improves insulin responsiveness. This formulation is unsuitable for managing type 1 diabetes.
Glycigon-M Tablet administration is linked to several common adverse reactions. These can manifest as low blood glucose, taste disturbances, nausea, abdominal discomfort, loose stools, cephalalgia, and upper respiratory infections. Serious, though infrequent, complications such as lactic acidosis may also occur. Prolonged therapy may additionally result in vitamin B12 depletion.
Glycigon-M Tablet use may result in hypoglycemia, characterized by low blood sugar. This can manifest as nausea, headache, irritability, hunger, sweating, dizziness, tachycardia, and anxiety or tremors. The risk increases with missed or delayed meals, alcohol consumption, excessive physical activity, or concomitant use of other antidiabetic medications. Consequently, consistent blood glucose monitoring is crucial. Carrying glucose tablets, honey, or fruit juice is recommended.
Glycigon-M Tablet use carries a risk of lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. Also termed Metformin-associated lactic acidosis (MALA), this is an infrequent adverse reaction to metformin. To mitigate risk, its use is contraindicated in individuals with pre-existing kidney impairment, the elderly, and those consuming substantial alcohol. Lactic acidosis symptoms can encompass muscle aches or weakness, vertigo, fatigue, cold extremities, respiratory distress, nausea, vomiting, abdominal pain, and bradycardia. Should these symptoms appear, discontinue Glycigon-M Tablet immediately and seek medical attention.
Glycigon-M Tablet use can lead to vitamin B12 deficiency over extended periods. This is because the medication impairs the stomach's absorption of vitamin B12. Untreated deficiency may result in anemia, neurological issues including tingling and numbness in the extremities, muscle weakness, urinary dysfunction, cognitive changes, and gait instability. To mitigate these risks, supplemental vitamin B12 is recommended annually by some experts.
Patients with hypersensitivity to any Glycigon-M Tablet ingredient or inactive component should not use this medication. Its use is also contraindicated in individuals with moderate to severe renal impairment or pre-existing metabolic acidosis, such as diabetic ketoacidosis.
Combining Glycigon-M Tablet and alcohol is unsafe. This combination risks dangerously low blood sugar and heightened lactic acidosis probability.
Glycigon-M tablets contain gliclazide and metformin, acting together to manage type 2 diabetes mellitus in adults. This dual-action therapy enhances blood sugar control when combined with a healthy diet and exercise regimen. Gliclazide stimulates insulin secretion from the pancreas, reducing blood glucose. Metformin functions by decreasing hepatic glucose production and increasing insulin responsiveness. This medication is unsuitable for type 1 diabetes.
Glycigon-M Tablet administration is linked to several reported side effects. These range from common occurrences such as low blood glucose, taste disturbances, queasiness, abdominal discomfort, loose stools, cephalalgia, and upper respiratory infections. Less frequent, but more serious adverse events, including lactic acidosis, have also been observed. Prolonged treatment may additionally result in vitamin B12 depletion.
Indeed, Glycigon-M Tablet use may lead to hypoglycemia, characterized by low blood glucose. Manifestations of low blood sugar include nausea, headache, irritability, hunger pangs, sweating, dizziness, tachycardia, and feelings of anxiety or tremor. This risk increases with skipped or delayed meals, alcohol consumption, excessive physical activity, or concomitant use of other antidiabetic medications. Therefore, consistent blood glucose monitoring is crucial. Carrying glucose tablets, honey, or fruit juice is advisable.
Glycigon-M Tablet use may result in lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. Also termed Metformin-associated lactic acidosis (MALA), this is an uncommon adverse reaction to metformin. Risk factors include pre-existing kidney disease, advanced age, and significant alcohol consumption. Symptoms can manifest as muscle aches or weakness, vertigo, fatigue, cold extremities, dyspnea, nausea, emesis, abdominal pain, or bradycardia. Should these symptoms occur, discontinue Glycigon-M Tablet and seek immediate medical attention.
Glycigon-M Tablet use is associated with vitamin B12 deficiency during prolonged treatment. This deficiency arises from the medication's interference with gastric vitamin B12 absorption. Untreated, this can lead to anemia, neurological complications such as paresthesia in the extremities, weakness, urinary dysfunction, cognitive impairment, and gait instability. Prophylactic annual supplemental vitamin B12 intake is recommended by some to mitigate these risks.
Patients exhibiting hypersensitivity to any Glycigon-M Tablet constituent or inactive ingredient should refrain from its use. Similarly, its administration is contraindicated in individuals with moderate to severe renal impairment or pre-existing metabolic acidosis, encompassing diabetic ketoacidosis.
Consuming alcohol concurrently with Glycigon-M Tablet is unsafe. This combination risks further lowering already low blood sugar, potentially inducing hypoglycemia, and elevating the likelihood of lactic acidosis.
Glycigon-M Tablet
84
MRP 103
18% off